Research summary
Testagen
A tetrapeptide also identified as KEDG. The available evidence is mainly animal or laboratory work from a limited research lineage. Human clinical benefit is not established.
Short Peptide BioregulatorSynthetic tetrapeptideAAs4MWSequence-dependent; verify the supplied formCASNot consistently reportedNCAAUnclear
Evidence at a glance
What the research says about Testagen
The Testagen evidence base cited here is 3 sources — 3 preclinical. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven.
Key findings
What the literature shows
- Testagen is commonly identified as the tetrapeptide KEDG: Lys-Glu-Asp-Gly.
- The available indexed evidence is mainly animal or laboratory research. One rat thyroid model reported changes after KEDG exposure.
- The evidence comes from a narrow research lineage. It does not establish a human clinical benefit.
Citations
3 peer-reviewed sources
All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.
Related research